



Dr. James J. Collins, a Pioneer in Synthetic Biology, Joins the Scientific Advisory Board of Agilis Biotherapeutics

New York, NY, March 5, 2014 – [Agilis Biotherapeutics, LLC](#), a synthetic biology-based company focused on developing DNA-based therapeutics for rare genetic diseases, announced today Professor James J. Collins, Ph.D., a pioneer in the field of synthetic biology, has joined its Scientific Advisory Board. Dr. Collins' scientific achievements and accomplishments have been recognized by numerous organizations for his groundbreaking work and fundamental discoveries in the field of synthetic biology.

Dr. Collins is an Investigator of the Howard Hughes Medical Institute and a William F. Warren Distinguished Professor, University Professor, Professor of Biomedical Engineering, Professor of Medicine and Co-Director of the Center for BioDynamics at Boston University. He is also a core founding faculty member of the Wyss Institute for Biologically Inspired Engineering at Harvard University. Dr. Collins' patented technologies have been licensed by over 25 biotechnology, pharmaceutical and medical devices companies, and he has helped to launch a number of companies. He has received numerous awards and honors, including a Rhodes Scholarship, a MacArthur "Genius" Award, an NIH Director's Pioneer Award, the World Technology Award in Biotechnology, as well as numerous teaching awards. Dr. Collins is a member of the National Academy of Engineering, the American Academy of Arts & Sciences, and the Institute of Medicine. His research group works in synthetic biology and systems biology.

"We are excited to welcome Dr. Collins, a scientific luminary and synthetic biology superstar, as a scientific advisor to the Company," said George S. Zorich, Chief Executive Officer of Agilis. "Dr. Collins brings substantial experience and expertise which we are confident will be invaluable to Agilis as we execute on our strategic initiatives."

"I am delighted to be joining Agilis at this pivotal stage in the Company's evolution," said Dr. Collins. "I look forward to helping guide the development of Agilis's potential breakthrough treatments with its collaborator [Intrexon Corporation \(NYSE: XON\)](#), as well as other life changing medicines for other life-threatening or fatal rare diseases utilizing synthetic biology."

About Agilis Biotherapeutics, LLC

Agilis Biotherapeutics, LLC, is a biotechnology company focused on designing and engineering first-in-class DNA-based therapeutics to improve and save the lives of patients affected by life-threatening or fatal rare diseases for which there are limited or no treatment options. We

believe that engineered DNA-based therapeutics provide the ability to target underlying disease mechanisms with tightly-controlled multigenic modalities leading to “functional cures” for patients with these diseases.

We invite you to visit our website at www.agilisbio.com

Safe Harbor Statement

Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development of our business. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release.

###

For more information contact:

Agilis Biotherapeutics

George S. Zorich

Chief Executive Officer

Email: gzorich@agilisbio.com

Phone: 847-274-6757